Elevated Expression of Growth Differentiation Factor-15 Is Associated With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Mengshu Cao1,2,3†, Lina Gu2†, Lili Guo4,†, Mengying Liu3, Tianzhen Wang3, Ji Zhang5, Huizhe Zhang2, Yufeng Zhang2, Yanchen Shi2, Yichao Zhao2, Xiaohua Qiu1, Xianhua Gui1, Miao Ma1, Yaqiong Tian1, Xiaoqin Liu1, Fanqing Meng6*, Yonglong Xiao1* and Lingyun Sun7*

1 Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China, 2 Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China, 3 Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China, 4 Department of Clinical Laboratory, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China, 5 Wuxi Transplant Center, Wuxi People’s Hospital Affiliated to Nanjing Medical University, Wuxi, China, 6 Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China, 7 Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

Backgrounds: Growth differentiation factor 15 (GDF-15) is a highly divergent member of the TGF-β superfamily and has been implicated in various biological functions. However, the expression of GDF-15 in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is unclear.

Method: The study included 47 AE-IPF patients, 61 stable IPF (S-IPF) subjects, and 31 healthy controls (HCs). Serum GDF-15 levels and their expression in the lung were measured. The correlation between serum GDF-15 and other clinical parameters and the risk factors for AE occurrence and the survival of IPF patients were analyzed.

Results: Serum GDF-15 levels were significantly elevated in AE-IPF patients (1279.22 ± 540.02 pg/ml) as compared with HCs (891.30 ± 479.90 pg/ml) or S-IPF subjects (107.82 ± 14.21 pg/ml) (both p < 0.001). The protein and mRNA expressions of GDF-15 in the lung of AE-IPF patients were significantly increased as compared with S-IPF cases (p = 0.007 and p = 0.026, respectively). The serum GDF-15 level was correlated with the clinical variables of inflammation, metabolism, and disease severity in IPF subjects (all p < 0.05). The GDF-15 serum concentration was significantly higher in decedents than in survivors (p = 0.005). A serum GDF-15 level above 989.3 pg/ml was a risk factor for AE occurrence (p = 0.04), and the level above 1,075.76 pg/ml was an independent predictor for survival in IPF cases (p = 0.007).
INTRODUCTION

Idiopathic pulmonary fibrosis (IPF) is the most common and devastating idiopathic interstitial lung disease (ILD), thus resulting in a progressive decline of respiratory function and early mortality (1). During the course of the disease, some cases may suffer an acute, clinically significant, respiratory deterioration with new widespread alveolar abnormality, referred to as acute exacerbation of IPF (AE-IPF) (2). The etiology of AE-IPF remains unclear. It may represent an intrinsic acceleration of the underlying fibrotic disease or a response to occult external events (e.g., infection, aspiration, and surgical operation) leading to acute lung injury (ALI) and histopathological diffuse alveolar damage (DAD), which shares the similar clinical and pathophysiological features with acute respiratory distress syndrome (ARDS) (3). AE is the primary cause of death in patients with this disorder (4). The incidence of AE is ranged from 7% to 32%, and nearly 46% of deaths in IPF patients are associated with AE in recent studies (1) and in-hospital mortality after AE exceeds 50% (5–7). Therefore, the incidences and predictors of AE are very important for clinicians who attempt to manage AE-IPF.

Growth differentiation factor 15 (GDF-15) is a divergent member of the transforming growth factor-β (TGF-β) superfamily, also named macrophage inhibitory cytokine-1 (MIC-1) (8). It is usually produced under stress conditions and has been involved in multiple biological processes, such as energy homeostasis, body weight regulation, and cachexia driven by cancer and chronic diseases (9). It has been linked to several acute and chronic pulmonary conditions, such as lung infection, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary embolism, pulmonary hypertension, and pulmonary fibrosis (9–12). From the data of lung genomics, GDF-15 is upregulated and expressed by epithelial cells in IPF. It is a useful biomarker of epithelial stress and can predict the poor outcomes in IPF patients (13). The association between aging and IPF is well established; GDF-15, the aging-related biomarker, has some of association with age, interstitial lung abnormalities, and mortality (14, 15). GDF-15, the aging-related biomarker, has some of association with acute exacerbation of IPF remains unknown. In present study, we aimed to explore the expression and potential role of GDF-15 in a Chinese cohort of AE-IPF subjects.

Conclusions: The GDF-15 level was significantly elevated in subjects with AE-IPF. GDF-15 could be a promising biomarker for AE occurrence and survival in IPF patients.

Keywords: growth differentiation factor 15, idiopathic pulmonary fibrosis, acute exacerbation, inflammation, metabolism

MATERIALS AND METHODS

Study Population

The current study recruited 108 IPF subjects (stable IPF, n = 47 and AE-IPF, n = 61) and 31 healthy controls (HCs) in Nanjing Drum Tower Hospital, Nanjing University Medical School from January 2015 to December 2018. The diagnoses criteria of IPF were based on the updated international practical guideline in 2018 (18) and AE-IPF was according to the international working group report in 2016 (2). Stable IPF (S-IPF) is referred to the clinical symptoms, chest imaging, and pulmonary function tests being stable at least 1 month before the samples of peripheral blood are obtained (19). Lung specimens were collected through surgical lung biopsy (SLB) or lung transplantation from the Nanjing Drum Tower Hospital and Wuxi People’s Hospital (lung cancer patients, normal lung tissues adjacent to cancer, n = 4; S-IPF subjects, n = 4 and AE-IPF cases, n = 4). Clinical data were collected from electronic medical records on admission and by a telephone follow-up. The current study was approved by the Ethics Committee of Nanjing Drum Tower Hospital in terms of the Declaration of Helsinki (1989) (NO.2016-160-01). All subjects signed the informed consent paperwork.

Assay of Serum GDF-15

The serum samples were collected, aliquoted, and stored at -80 °C. The date of sample collection was the day following admission (S-IPF patients who were admitted for diagnoses or evaluating on conditions). The serum concentrations of GDF-15 (DY957; R&D Systems, Minneapolis, United States) and leptin (ab108879; Millipore Corporation, Massachusetts, United States) were measured using enzyme-linked immunosorbent assay (ELISA) kits on the basis of the manufacturer’s instructions. Each sample was assayed in duplicate.

GDF-15 MEASUREMENT IN LUNG TISSUES

Quantitative real-time PCR (RT-PCR) and western blot (WB) were used to detect the mRNA and protein expression of GDF-15 in the lung from IPF patients and HCs as described previously (20). Immunohistochemistry (IHC) was employed to determine the location of GDF-15 expression in the lung. Total RNA was isolated from frozen lung tissues with a Trizol reagent (15596026 and 15596018) (Invitrogen, California, United States). The primers are right were designed and synthesized by TaKaRa Biotechnology Co, Ltd. (Dalian, China). The primers of human GDF-15 were forward GACCCTCAGATTGCACCTCC and reverse GCCCTGGTAGCAGGTCTCT, and for GAPDH, they were forward GGAGCGAGATCCCTCAAAT and reverse GGCTGGTGTCAATCTCATG, respectively. The anti-GDF-15 (ab189358; Abcam, Boston, United States) and...
GAPDH (14C10, CST, Boston, United States) were used in WB and anti-GDF-15 (NB1-81050; Novus Biologicals, Colorado, United States) was employed in IHC as the primary antibodies. Goat anti-rabbit and rabbit anti-mouse secondary antibodies (7076S and 7074S; CST, Boston, United States) were used. The percentages of GDF-15 positive expressing cells in lung tissue were analyzed by software Image-Pro Plus (6.0 version).

**Collection of Clinical Data**
Clinical data were collected from electronic medical records. The vital status was determined from medical records or a telephone follow-up. The deadline of the follow-up was November 17, 2019. The duration of survival was from the date of sample collection to the date of death or vital status confirmed. Concurrent infection was defined as patients with clinical symptoms of fever or/and purulent sputum, elevated white blood cell (WBC) counts, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and/or lactate dehydrogenase (LDH), or positive pathogen tests.

**Assessment of Disease Severity**
The scores of gender-age-physiology (GAP) and chest high-resolution computed tomography (HRCT) were used to assess the disease severity of IPF patients. The total GAP score was calculated by the method proposed by Ley et al. (21). Chest HRCT was performed with 1.0–1.5 mm thick sections and appropriate window settings (window width: 1,600, window level: -600). The images were evaluated for the extents of GGO, consolidation, reticulation, traction bronchiectasis, honeycombing, and emphysema. The chest HRCT scores were assessed according to the published study by Lynch et al. (22).

**Statistical Analysis**
The categorical variables were presented as numbers and percentages, and continuous variables were expressed as the mean ± standard deviation (SD). The comparisons of the differences of categorical parameters were assessed by the chi-square ($\chi^2$) or Fisher exact test, and continuous variables were evaluated by independent sample t-test, Kruskal–Wallis, Mann–Whitney U test, or one-way ANOVA test. The correlations between serum GDF-15 and other clinical variables were assessed by Spearman’s or Pearson’s correlation analysis depending on the distribution of the variables. The survival curves were generated by Kaplan–Meier methods and compared by the log-rank test. The optimal cut-off value for predicting AE occurrence and the mortality was determined by receiver operating characteristic (ROC) curve. Logistic models were used to analyze the risk factors for AE and Cox regression models were built to examine the predictors of time-to-death in IPF patients. p < 0.05 was considered to be statistically significant. Statistical analyses were performed by IBM SPSS version 21 (SPSS, Inc., Chicago IL, United States) and Prism version 8 (GraphPad, San Diego, CA, United States).

**RESULTS**

**Baseline Characteristics in HCs, S-IPF, and AE-IPF Patients**
As shown in Supplementary Table 1, the differences of gender and age in the three groups (HCs, S-IPF, and AE-IPF groups) were not significant (p = 0.794 and p = 0.085, respectively). However, there were significant differences in GDF-15 serum levels, WBC counts, triglyceride (TG), total cholesterol (TCHL), low cholesterol (LCHL), and glucose (GLU), which are related to infection and metabolism (p < 0.001, p < 0.001, p = 0.003, p = 0.014, p = 0.022, and p < 0.001, respectively). The differences of complication and prior antifibrotic use between patients with S-IPF and AE-IPF were not significant (p = 0.438 and p = 0.438, respectively).

**The Differences of Clinical Parameters Related to Infection and Inflammation, Metabolism, and Disease Severity Were Significant Between S-IPF and AE-IPF Patients**
Between S-IPF and AE-IPF subjects, we compared the differences in the clinical variables of demography, inflammation, metabolism, and disease severity. The differences of gender, age, and smoking in patients between the two groups were not significant (p = 0.837, p = 0.308, and p = 0.971, respectively) (Table 1). Among the numbers of clinical variables associated with inflammation and infection, cases with prior corticosteroid use and fever in the AE-IPF group were significantly more than those in the S-IPF group (p = 0.002 and p < 0.001, respectively). In AE-IPF subjects, the CD4+ lymphocyte counts were significantly lower (p < 0.001), while the inflammatory indicators of WBC counts, CRP, ESR, and LDH were significantly increased compared with S-IPF cases (all p < 0.001). The clinical variables associated with metabolism, including TG, Apo AI, and AIB were significantly lower (p = 0.008, p = 0.023, and p < 0.001, respectively) and GLU was significantly higher in the AE-IPF group than those in the S-IPF group (p < 0.001). The clinical parameters related to the disease severity of IPF, including the PaO2/FiO2 ratio, D-dimer, HRCT score, pulmonary arterial pressure (PAH), forced vital capacity (FVC), carbon monoxide-diffusing capacity (DLCO), GAP scores, and stages were significantly worse in the AE-IPF group compared with the controls (all p < 0.05) (Table 1).

**The Expressions of GDF-15 Were Significantly Elevated in AE-IPF Patients**
The serum level of GDF-15 in AE-IPF patients (1,279.22 ± 540.02 pg/ml) was significantly elevated compared with S-IPF subjects (891.30 ± 479.90 pg/ml) or HCs (107.82 ± 14.21 pg/ml) (p < 0.001 and p < 0.001, respectively) (Figure 1A). The differences of GDF-15 concentrations were not significant in IPF cases with different gender, age, and smoking history (p = 0.508, p = 0.869 and p = 0.409, respectively) (Figures 1B–D). The serum levels of both GDF-15 and leptin were increased (Supplementary Figure 1A). GDF-15 serum levels were significantly negatively correlated with leptin in AE-IPF subjects (r = - 0.329, p = 0.024) (Supplementary Figure 1B) but not in S-IPF or HC cases (r = 0.180, p = 0.168 and r = - 0.345, p = 0.062, respectively) (Supplementary Figures 1C–D).

The protein and mRNA expressions of GDF-15 in the lung of AE-IPF subjects were increased significantly compared with HCs
TABLE 1 | Comparison of clinical features between S-IPF and AE-IPF patients.

| Clinical variables                  | S-IPF group | AE-IPF group | p-value |
|-------------------------------------|-------------|--------------|---------|
| Population demography               |             |              |         |
| Gender (M/F)                        | 49/12       | 37/10        | 0.837   |
| Age (years)                         | 67.0 ± 8.3  | 68.5 ± 7.2   | 0.308   |
| Smoking (pack-years)                | 16.8 ± 21.5 | 16.9 ± 22.0  | 0.971   |
| Inflammation and infection          |             |              |         |
| Concurrent infection                | 9/52        | 26/21        | <0.001  |
| Prior corticosteroid use (Y/N)      | 27/34       | 35/12        | 0.002   |
| Fever (Y/N)                         | 3/58        | 19/28        | <0.001  |
| CD4+ lymphocyte counts (×10⁹)       | 0.703 ± 0.281| 0.352 ± 0.302| <0.001  |
| WBC counts (×10⁹)                   | 6.50 (2.6-11.3)| 10 (2.7-20.1)| <0.001  |
| CRP (mg/L)                          | 3.50 (1.0-126.5)| 17.5 (1.0-442.6)| <0.001  |
| ESR (mm/h)                          | 15 (0-84)   | 38 (2-94)    | <0.001  |
| LDH (U/L)                           | 231 (166-407)| 389 (181-1267)| <0.001  |
| Metabolism                          |             |              |         |
| TG (mmol/L)                         | 1.56 ± 1.12 | 1.09 ± 0.85 | 0.008   |
| Apo Al (g/L)                        | 1.10 ± 0.30 | 0.97 ± 0.28 | 0.023   |
| AIB (g/L)                           | 39.36 ± 4.09| 33.13 ± 5.58| <0.001  |
| GLU (mmol/L)                        | 4.86 (3.53-13.84)| 5.83 (2.03-17.67)| <0.001  |
| Disease severity                    |             |              |         |
| PaO₂/FiO₂ ratio                     | 357 (224-476)| 195 (49.0-496.0)| <0.001  |
| D-dimer (mg/L)                      | 0.35 (0.11-2.52)| 1.05 (0.21-28.96)| <0.001  |
| HRCT Score                          | 3.46 ± 1.27 | 6.57 ± 1.16 | <0.001  |
| PAH (<40/≥40 mmHg)                  | 44/4        | 14/18        | <0.001  |
| PVC (L)                             | 2.33 ± 0.83 (59)| 1.76 ± 0.53 (34)| 0.001   |
| DLCO % pred                         | 55.95 ± 20.08 (54)| 34.92 ± 19.53 (25)| <0.001  |
| GAP scores                          | 3.71 ± 1.67 | 5.39 ± 1.71 | <0.001  |
| GAP stage (I/II/III)                | 28/22/8     | 5/11/17      | <0.001  |

and S-IPF cases by WB and RT-PCR (p < 0.001, p = 0.007 and p < 0.001, p = 0.026, respectively) (Figures 2A–C). Immunohistochemistry (IHC) staining showed the moderately positive expressions of GDF-15 in the cytoplasm of type II alveolar epithelial cells (AECs) and macrophages of HCs (Figure 2D, ×200), moderately positive expressions in inflammatory cells and macrophages in the alveolar septum and mild positive expression in the bronchial epithelial cells.
and fibroblasts of an S-IPF patient (Figure 2E, ×200), while there were moderately positive expressions in inflammatory cells, macrophages, and fibroblasts in the interstitial spaces (Figure 2F, ×200) and the bronchial epithelial cells of AE-IPF subjects (Figure 2G, ×400). The percentages of GDF-15-expressing cells in the lung of AE-IPF patients (23.67 ± 1.43%) were more than both HCs (15.34 ± 1.38%) and S-IPF (17.66 ± 1.10%) subjects (p < 0.001 and p < 0.001, respectively) (5 fields each sample).

![FIGURE 2 | GDF-15 expression in the lung of IPF patients.](image)

(A) GDF-15 protein expression in the lung tissues of subjects with HC, S-IPF, and AE-IPF by WB. (B) The quantification of A showed that the protein expression of GDF-15 was significantly upregulated in AE-IPF patients compared with S-IPF subjects and HCs (p = 0.007 and p < 0.001, respectively). (C) GDF-15 mRNA expression in the lung of AE-IPF patients was significantly increased compared with HC, S-IPF cases by RT-PCR (p < 0.001 and p < 0.026, respectively) (n = 4, each group). (D-G) GDF-15 expression in the lung measured by IHC. (D) The moderately positive expressions of GDF-15 in the cytoplasm of type II AECs and macrophages in HC (IHC, ×200). (E) The moderately positive expressions of GDF-15 in inflammatory cells and macrophages in the alveolar septum and mild positive expressions in the bronchial epithelial cells and fibroblasts in S-IPF patients (IHC, ×200). (F) GDF-15 moderately positive expressions in inflammatory cells, macrophages, and fibroblasts in the interstitial spaces in AE-IPF case (IHC, ×200). (G) The moderately positive expressions of GDF-15 in the bronchial epithelial cells and fibroblasts in the same AE-IPF patient as Figure 2F (IHC, ×400). (Notes: macrophages ; type II AEC ; inflammatory cell ; bronchial mucosa epithelial cells ; fibroblast ).
Serum GDF-15 Levels Correlated With the Clinical Variables of Inflammation, Metabolism, and Disease Severity in IPF Patients

As shown in Table 2, serum GDF-15 concentrations did not show any correlation with population demographic parameters, gender, age, and smoking status in all IPF patients. However, it was positively correlated with several clinical parameters of infection and inflammation (ESR, CRP, LDH, and PCT) ($r = 0.314$, $p = 0.001$) and negatively correlated with metabolic indicators (TG, TC, LCHL, Apo B, and ALB) ($r = -0.229$, $p = 0.017$). Serum GDF-15 was positively correlated with several clinical parameters of gender, age, and smoking status in all IPF patients. However, it did not show any correlation with population demographic parameters, gender, age, and smoking status in all IPF patients. Furthermore, serum GDF-15 levels were significantly correlated with the clinical variables of disease severity (D-dimer, PaO2/FiO2, HRCT score, PAH, FVC % pred, TLC % pred, DLCO % pred, and GAP stages) (all $p < 0.05$).

### Serum GDF-15 Is a Risk Factor for AE Occurrence in IPF Patients

The areas under the ROC curves of serum GDF-15 levels were statistically significant in the classification of AE-IPF (n = 47) or S-IPF patients (n = 61) (ROC: 0.738, $p < 0.001$, 95% CI: 0.529-0.895). Our study showed that the clinical parameters related to inflammation (WBC counts, CRP, ESR, and LDH, PCT), body metabolism (TG, Apo AI, AIB, and GLU), and disease severity (D-dimer, PaO2/FiO2, HRCT score, PAH, FVC, DLCO, GAP scores, and stages) were significantly different between patients with S-IPF and AE-IPF. The published data showed that poor pulmonary physiological function, mechanical procedures, and pulmonary hypertension were associated with

### Table 2: Bivariate correlation analysis between serum GDF-15 and clinical variables in IPF patients.

| Clinical variables               | r    | p-value |
|----------------------------------|------|---------|
| Population demography            |      |         |
| Gender                           | -0.084 | 0.507  |
| Age (years)                      | -0.021 | 0.832  |
| Smoking (pack*years)             | 0.046  | 0.634  |
| Inflammation and infection       |      |         |
| WBC counts ($x10^9$)             | 0.125  | 0.196  |
| ESR (mm/h)                       | 0.314  | 0.001  |
| CRP (mg/L)                       | 0.376  | <0.001 |
| LDH (U/L)                        | 0.272  | 0.004  |
| PCT                              | 0.426  | 0.01   |
| Metabolism                       |      |         |
| TG (mmol/L)                      | -0.201 | 0.037  |
| TC (mmol/L)                      | -0.229 | 0.017  |
| TCHL (mmol/L)                    | -0.100 | 0.302  |
| LDL (mmol/L)                     | -0.255 | 0.008  |
| Apo A (g/L)                      | -0.185 | 0.066  |
| Apo B (g/L)                      | -0.242 | 0.011  |
| ALB (g/L)                        | -0.318 | 0.001  |
| GLU (mmol/L)                     | -0.018 | 0.850  |
| Disease severity                 |      |         |
| D-dimer (mg/L)                   | 0.281  | 0.004  |
| PaO2/FiO2 ratio                  | -0.297 | 0.003  |
| HRCT score                       | 0.330  | 0.001  |
| PAH (mmHg)                       | 0.322  | 0.004  |
| FVC % pred                       | -0.222 | 0.033  |
| TLC % pred                       | -0.325 | 0.003  |
| DLCO % pred                      | -0.359 | 0.001  |
| GAP stage (I/II/III)             | 0.305  | 0.003  |

**DISCUSSION**

GDF-15 has been indicated in various biological functions, including inflammation, metabolism, cancer cachexia, solid tumor, renal and heart failure, atherosclerosis, and lung fibrosis (11, 23, 24). In our study, the differences of clinical parameters associated with infection and inflammation, metabolism, disease severity, and clinical outcomes were significantly different between patients with AE-IPF and S-IPF. The expression of GDF-15 was increased in AE-IPF cases and the serum GDF-15 level correlated with the clinical variables of inflammation, metabolism, disease severity, and survival of IPF subjects. GDF-15 could be a potential predictor for AE occurrence and survival in IPF patients.

AE is usually a devastating complication for IPF patients (2). Although the tyrosine kinase inhibitor can decrease the incidence of AE, there is still no optimal therapy for AE-IPF (2, 25). The etiology of AE-IPF remains uncertain. Infection, micro-aspiration, and intrinsic biological dysfunction of the lung have been identified as associated with AE in IPF patients (2, 26-29). Our study showed that the clinical parameters related to infection and inflammation (WBC counts, CRP, ESR, and LDH), body metabolism (TG, Apo AI, AIB, and GLU), and disease severity (D-dimer, PaO2/FiO2 ratio, HRCT score, PAH, FVC, DLCO, GAP scores, and stages) were significantly different between patients with S-IPF and AE-IPF. The published data showed that poor pulmonary physiological function, mechanical procedures, and pulmonary hypertension were associated with
The development of AE may be related to inflammation and worse pulmonary physiological function, which can cause metabolic disorders. All the above conditions may lead to a vicious cycle and AE occurrence in IPF patients. Our previous studies indicated that leptin and osteopontin may be the valuable biomarkers for AE-IPF patients (19, 32). However, whether these factors are involved in the development of AE-IPF needs further study in the future. GDF-15 is secreted from senescent AECs and is an aging-related biomarker of IPF (11, 13, 15). Data showed that it might act as a profibrotic risk factor via the activation of M2 macrophages and fibroblasts (11). The elevated serum levels of GDF-15 in COVID-19 patients with ARDS indicated that GDF-15 may be associated with ARDS caused by a virus infection (16, 17). The respiratory infection is closely related to the development of AE for IPF patients. Therefore, GDF-15 may be an important trigger factor in the pathogenesis of AE-IPF. GDF-15 serum levels and expression in the lung tissues of AE-IPF patients were significantly elevated in

### TABLE 3 | Risk factors for AE by logistic regression analysis in patients with IPF.

| Clinical Variables          | Univariate Logistic Analysis | Multivariate Logistic Analysis |
|-----------------------------|------------------------------|--------------------------------|
|                             | HR              | 95.0% CI | p-value | HR              | 95.0% CI | p-value |
| Prior corticosteroid use     | 3.673           | 1.805-8.404 | 0.002 | 5.236           | 0.799-34.326 | 0.084 |
| PaO₂/FiO₂ (<300)            | 0.011           | 0.003-0.043 | <0.001 | 0.021           | 0.004-0.106 | <0.001 |
| GAP stage (I/II/III)         | 5.227           | 1.771-15.422 | 0.003 | 2.426           | 0.798-7.542 | 0.117 |
| Serum GDF-15 (>989.3 pg/ml) | 0.246           | 0.110-0.553 | 0.001 | 0.148           | 0.024-0.914 | 0.040 |
energy metabolism (10, 12, 16, 38). Wu et al. demonstrated that GDF-15 levels were elevated in COVID-19 patients (16). In our cohort study of IPF patients, GDF-15 showed its broad anti-inflammatory roles in different contexts. The ample evidence above indicates that GDF-15 may be involved in the initiation stage of AE and upregulation of GDF-15 in IPF subjects, which can further cause metabolic disorders of lipid and protein and coagulation dysfunction and then aggravate the conditions of these patients. Moreover, these factors may interact with each other and make the clinical conditions of these patients continuously worse under poor pulmonary physiological function.

Serum GDF-15 levels in AE-IPF subjects were not related to smoking in the current study. The published data showed that GDF-15 levels were higher in COPD patients and cigarette smoke (CS)-exposed mice, and increased GDF-15 expression may contribute to CS-induced pulmonary inflammation (43). GDF-15 was directly involved in the production of proinflammatory cytokines and chemokines, such as IL-6 and CCL2 in bleomycin-induced mice and systemic sclerosis (SSc) patients with lung involvement (37). The elevated GDF-15 expression in the lung of IPF patients may trigger inflammation and aggravate disease development (37). Our study demonstrated that serum GDF-15 levels above 989.3 pg/ml can predict AE occurrence in IPF patients. The findings of current and published studies support that the elevated expressions of GDF-15 may be associated with the development of AE by regulating the inflammatory response in IPF patients.

The circulating GDF-15 levels have a close correlation with known markers of fibrosis such as type I collagen and osteopontin (37). GDF-15 expression was induced during fibrosis development and markedly associated with reduced lung function in SSc patients (37). GDF-15 could be a useful biomarker for IPF patients with poor outcomes (13). The short- and long-term clinical outcomes of AE-IPF subjects were all significantly worse than S-IPF cases in our study, consistent with the previous reports (19, 32). ROC curves also demonstrated that serum GDF-15 can predict the survival of IPF patients. The patients with serum GDF-15 levels above 1,075.76 pg/ml had significantly worse survival, and it was an independent risk factor for survival after controlling for other known predictors in IPF patients. We suggest that serum GDF-15 may be a promising biomarker for the survival of IPF subjects.

The present study has some limitations. First, the sample was small and all patients were from the same center. We have no data of serum GDF-15 concentrations from the same patient in different clinical conditions (such as before, during, and after AE), which would be helpful to further support the utility of GDF-15 as a biomarker of IPF. A prospective and multicenter study of a larger sample cohort would be beneficial to provide additional evidence on GDF-15.

**CONCLUSIONS**

In summary, the expressions of GDF-15 were increased significantly in patients with AE-IPF. An elevated serum GDF-15 level was associated with infection and inflammation.
metabolism indicators, and the disease severity of IPF and could predict AE occurrence and the survival in IPF subjects.

ACKNOWLEDGMENTS

The authors would like to thank all patients for sending their consents. This work has been presented in the form of one late-breaking abstract at the European Respiratory Society Congress 2019 in Madrid.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Nanjing Drum Tower Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

REFERENCES

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management. *Am J Respir Crit Care Med* (2011) 183(6):788–824. doi: 10.1164/rccm.2009-040GL
2. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Konodoh Y, Lederer DJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am J Respir Crit Care Med* (2016) 194(3):265–75. doi: 10.1164/rccm.201604-0811CI
3. Marchioni A, Tonelli R, Ball L, Fantini R, Castaniere I, Cerri S, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Lessons Learned From Acute Respiratory Distress Syndrome? *Crit Care* (2018) 22(1):80. doi: 10.1186/s13054-018-2002-4
4. Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: International Survey and Call for Harmonisation. *Eur Respir J* (2020) 55(4):1901760. doi: 10.1183/13993003.01760-2019
5. Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, et al. Acute Exacerbations in the INPULSIS Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. *Eur Respir J* (2017) 49(5):1601339. doi: 10.1183/13993003.01339-2016
6. Wu Q, Jiang D, Schaefer NR, Harmacek L, O'Connor BP, Eling TE, et al. Overproduction of Growth Differentiation Factor 15 Promotes Human Rhinovirus Infection and Virus-Induced Inflammation in the Lung. *Am J Physiol Lung Cell Mol Physiol* (2018) 314(3):L510–27. doi: 10.1152/ajplung.00324.2017
7. Zhang Y, Jiang M, Nouraie M, Roth MG, Tabib T, Winters S, et al. GDF-15 is an Epithelial-Derived Biomarker of Idiopathic Pulmonary Fibrosis. *Am J Physiol Lung Cell Mol Physiol* (2019) 317(4):L514–27. doi: 10.1152/ajplung.00034.2019
8. Cao MS, Sheng J, Wang TZ, Qiu XH, Wang DM, Wang Y, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Usual Interstitial Pneumonitis vs. Possible Usual Interstitial Pneumonitis Pattern. *Chin Med J* (2019) 132(18):2177–84. doi: 10.1097/CMA.0000000000000422
9. Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: International Survey and Call for Harmonisation. *Eur Respir J* (2020) 55(4):1901760. doi: 10.1183/13993003.01760-2019
10. Wu Q, Jiang D, Schaefer NR, Harmacek L, O’Connor BP, Eling TE, et al. Overproduction of Growth Differentiation Factor 15 Promotes Human Rhinovirus Infection and Virus-Induced Inflammation in the Lung. *Am J Physiol Lung Cell Mol Physiol* (2018) 314(3):L510–27. doi: 10.1152/ajplung.00324.2017
11. Takenouchi Y, Kitake K, Tsuboi K, Okamoto Y. Growth Differentiation Factor 15 Facilitates Lung Fibrosis by Activating Macrophages and Fibroblasts. *Exp Cell Res* (2020) 391(2):112010. doi: 10.1016/j.yexcr.2020.112010
12. Wu Q, Jiang D, Schaefer NR, Harmacek L, O’Connor BP, Eling TE, et al. Overproduction of Growth Differentiation Factor 15 Promotes Human Rhinovirus Infection and Virus-Induced Inflammation in the Lung. *Am J Physiol Lung Cell Mol Physiol* (2018) 314(3):L510–27. doi: 10.1152/ajplung.00324.2017
13. Zhang Y, Jiang M, Nouraie M, Roth MG, Tabib T, Winters S, et al. GDF-15 is an Epithelial-Derived Biomarker of Idiopathic Pulmonary Fibrosis. *Am J Physiol Lung Cell Mol Physiol* (2019) 317(4):L514–27. doi: 10.1152/ajplung.00034.2019
14. Gulati S, Thannickal VJ. The Aging Lung and Idiopathic Pulmonary Fibrosis. *Am J Med Sci* (2019) 357(5):384–9. doi: 10.1097/AMJ.0000000000002008
15. Sanders JL, Putman RK, Dupuis J, Xu H, Murabito JM, Araki T, et al. The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and...
Cao et al. Elevated GDF-15 Expression in AE-IPF

Mortality. Am J Respir Crit Care Med (2021) 203(9):1149–57. doi: 10.1164/rccm.202007-2993OC

16. Notz Q, Schmalzing M, Wedekind F, Schlesinger T, Gernert M, Herrmann J, et al. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. Front Immunol (2020) 11:581338. doi: 10.3389/fimmu.2020.581338

17. Luis García de Guadiana R, Mulero MDR, Olivo MH, Rojas CR, Arenas VR, Morales MG, et al. Circulating Levels of GDF-15 and Calprotectin for Prediction of in-Hospital Mortality in COVID-19 Patients: A Case Series. J Infect (2021) 82(2):e40–2. doi: 10.1016/j.jinf.2020.08.010

18. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Remy CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med (2018) 198(5):e44–68. doi: 10.1164/rccm.201807-1235SS

19. Cao M, Swigiris JJ, Wang X, Cao M, Qiu Y, Huang M, et al. Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators Inflamm (2016) 2016:6940480. doi: 10.1155/2016/6940480

20. D'Alessandro-Gabazza CN, Kobayashi T, Yasuma T, Toda M, Kim H, et al. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. Front Immunol (2020) 11:581338. doi: 10.3389/fimmu.2020.581338

21. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis. Ann Intern Med (2012) 156(10):684–91. doi: 10.7326/0003-4819-156-10-201205150-00004

22. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, et al. Acid Treatment and Disease Progression in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Am J Respir Crit Care Med (2012) 186(10):1156–62. doi: 10.1164/rccm.201205-0825OC

23. Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, et al. The Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Respirology (2014) 370(22):2071–81. doi: 10.1111/resp.12691

24. de Jager SC A, Bermudez A, Bot I, Koenen RR, Bot M, Kavelaars A, et al. Growth Differentiation Factor 15, a Marker of Lung Involvement in Systemic Sclerosis, is Involved in Fibrosis Development But is Not Indispensable for Fibrosis Development. Arthritis Rheumatol (2014) 66(2):418–27. doi: 10.1002/art.38241

25. Baek SJ, Eling T. Growth Differentiation Factor 15 (GDF-15): A Survival Protein With Therapeutic Potential in Metabolic Diseases. Pharmacol Ther (2019) 198:46–58. doi: 10.1016/j.pharmthera.2019.02.008

26. Emberson PJ, Duffin KL, Chinharlapalli S, Wu X. GDF-15 and Growth Control. Front Physiol (2018) 9:1712. doi: 10.3389/fphys.2018.01712

27. de Jager SC A, Bermudez A, Bot I, Koenen RR, Bot M, Kavelaars A, et al. Growth Differentiation Factor 15 Deficiency Protects Against Atherosclerosis by Attenuating CCR2-Mediated Macrophage Chemotaxis. J Exp Med (2011) 208(2):217–25. doi: 10.1084/jem.20100255

28. Bonaterra GA, Zügel S, Thogersen J, Walter SA, Haberkorn U, Streulau J, et al. Growth Differentiation Factor-15 Deficiency Inhibits Atherosclerosis Progression by Regulating Interleukin-6-Dependent Inflammatory Response to Vascular Injury. J Am Heart Assoc (2012) 1(6):e002550. doi: 10.1161/JAHA.112.002550

29. Tektonidou MG, Papassotiriou I, Silkakis PP. Growth Differentiation Factor 15 (GDF-15) as Potential Cardiovascular Risk Biomarker in Antiphospholipid Syndrome. Rheumatol (Oxford England) (2021) 61(19):394–9. doi: 10.1093/rheumatology/keab277

30. Verhamme FM, Seys LJM, De Smet EG, Provoost S, Janssens W, Elewaut D, et al. Growth Differentiation Factor-15 Depletion Protects Against Atherosclerosis Upon Cigarette Smoke Exposure. Mucosal Immunol (2017) 10(6):1400–11. doi: 10.1038/mi.2017.3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cao, Gu, Guo, Liu, Wang, Zhang, Zhang, Shi, Zhao, Qiu, Gu, Ma, Tian, Liu, Meng, Xiao and San. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.